We are live on ! Find out more
AI

Alphabet Inc Portfolio holdings

AUM $4.02B
1-Year Est. Return 215.74%
This Fund
S&P 500
This Quarter Est. Return
+36.23%
1 Year Est. Return
+215.74%
3 Year Est. Return
+350.01%
5 Year Est. Return
+242.03%
10 Year Est. Return
+998.87%
AUM
$2.41B
AUM Growth
+$273M
Cap. Flow
-$130M
Cap. Flow %
-5.39%
Top 10 Hldgs %
89.13%
Holding
38
New
2
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$29.4M
2
FIG
Figma
FIG
+$14.8M
3
PRME icon
Prime Medicine
PRME
+$6.09M

Top Sells

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$137M
2
MTSR
Metsera Inc
MTSR
+$43.5M

Sector Composition

Rank Sector Weight
1 Technology 47.13%
2 Healthcare 35.65%
3 Industrials 17.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCRX icon
26
TScan Therapeutics
TCRX
$50.2M
$1.96M 0.08%
1,077,080
– –
BRNS
27
Barinthus Biotherapeutics
BRNS
$24.6M
$1.89M 0.08%
1,513,644
– –
SPRO icon
28
Spero Therapeutics
SPRO
$68.3M
$1.67M 0.07%
889,979
– –
TNYA icon
29
Tenaya Therapeutics
TNYA
$167M
$1.48M 0.06%
915,705
– –
HYPR icon
30
Hyperfine
HYPR
$95.3M
$1.3M 0.05%
898,720
– –
EXAS
31
DELISTED
Exact Sciences
EXAS
$1.27M 0.05%
23,205
– –
AUTL
32
Autolus Therapeutics
AUTL
$389M
$1.14M 0.05%
698,262
– –
GUTS icon
33
Fractyl Health
GUTS
$127M
$1.05M 0.04%
662,584
– –
ALEC icon
34
Alector
ALEC
$168M
$521K 0.02%
175,866
– –
QNCX icon
35
Quince Therapeutics
QNCX
$17.5M
$308K 0.01%
946
– –
FULC icon
36
Fulcrum Therapeutics
FULC
$249M
$131K 0.01%
14,262
– –
RGEN icon
37
Repligen
RGEN
$7.39B
$51.2K ﹤0.01%
383
– –
VERV
38
DELISTED
Verve Therapeutics
VERV
– –
-12,168,489
Closed -$137M
1
2

Similar funds

JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
MAM
Martingale Asset Management Boston, Massachusetts $3.99B AUM 22.65% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
ICP
Ilex Capital Partners London, United Kingdom $4.06B AUM 6.11% 1-Year Est. Return
CA
CSM Advisors Warrendale, Pennsylvania $4.07B AUM 29.62% 1-Year Est. Return
MGP
Metis Global Partners San Diego, California $4.07B AUM 30.82% 1-Year Est. Return

Alphabet Inc's Q3 2025 Portfolio in Review

As of Q3 2025, Alphabet Inc held 38 positions worth $2.41B, up 13% from $2.14B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Alphabet Inc withdrew a net $130M in Q3 2025, closing 1 position and reducing 1 holding. Its most notable exit was Verve Therapeutics, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Technology at 47% of assets, down from 56% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Alphabet Inc opened a new position in BridgeBio Oncology worth $32.7M.

  • Alphabet Inc's largest Q3 2025 buy was BridgeBio Oncology: 2,823,126 shares worth $32.7M.
  • Alphabet Inc added most to Prime Medicine in Q3 2025, an estimated $6.09M increase.
  • Alphabet Inc's biggest Q3 2025 reduction was Metsera Inc, cutting an estimated $43.5M.
  • Alphabet Inc fully exited Verve Therapeutics in Q3 2025, selling an estimated $137M.
  • Alphabet Inc's ten largest holdings make up 89% of its $2.41B portfolio in Q3 2025.
  • Alphabet Inc opened 2 new positions and closed 1 in Q3 2025.
  • Alphabet Inc's portfolio value rose 13% quarter-over-quarter to $2.41B.

Based on Alphabet Inc's 13F filing for Q3 2025, filed 7 Nov 2025.